A 2013 publication showed a reduced relapse incidence in systemic lupus erythematosus (SLE) patients undergoing AHSCT with CD34+ selection (11 vs. 68%); however, a greater proportion of the non-graft selected patients had received a low-intensity conditioning regimen (123). The gene discussed is CD34; the disease is systemic lupus erythematosus.